Indapamide
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1983
- First approval year
- 1983
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Indapamide
- Molecular weight
- 365.84
- Structure (SMILES)
- CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(S(N)(=O)=O)c1
- cardide sr
- Cardide sr
- ethibide xl
- Ethibide xl
- indapamide
- Indapamide
- indapamide component of br 1015
- Indapamide component of br-1015
- indaxa 2 5
- Indaxa 2.5
- indipam xl
- Indipam xl
- lozol
- Lozol
- mapemid xl
- Mapemid xl
- natrilix
- Natrilix
- natrilix sr
- Natrilix sr
- nindaxa 2 5
- Nindaxa 2.5
- opumide 2 5
- Opumide 2.5
- rawel xl
And 5 more, listed on the interactive page.
- allisartan 240mg indapamide 1 5mg
- arifon
- Arifon
- bajaten
- Bajaten
- br 1015 component indapamide
- BR-1015 component Indapamide
- damide
- Damide
- fimasartan indapamide
- flubest
- Flubest
- fludex
- Fludex
- fludin
- Fludin
- flupamid
- Flupamid
- indaflex
- Indaflex
- indamide
- Indamide
- indamol
- Indamol
- indapamida
And 54 more, listed on the interactive page.
- ATC classification codes
- C03BA11
Sources for recorded values
- CAS registry numbers
- 26807-65-8
- ChEMBL ID
- CHEMBL406
- InChIKey
- NDDAHWYSQHTHNT-UHFFFAOYSA-N
- PubChem compound IDs
- 3702
- RxNorm IDs (RxCUI)
- 5764
- FDA ingredient codes (UNII)
- F089I0511L
- Applicant
- AZURITY
- Approval date
- 5 Jun 2025
- Application number
- NDA219423
- Patents
- 3
- Designations
- 0
- Earliest recorded loss of exclusivity
- 23 Jan 2038
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Pharmacology name
- indapamide
- Type
- Synthetic organic
- Drug name stem
- -pamide
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Action
- Binding
- Action type
- Binding
- Target
- N-Acylphosphatidylethanolamine-phospholipase D
- Gene symbol
- NAPEPLD
- Protein identifier
- Q6IQ20
- Median affinity
- 6.24
- Affinity units
- pKd
- Mechanism
- Thiazide-sensitive sodium-chloride cotransporter inhibitor
- Action type
- Inhibitor
- Target
- Solute carrier family 12 member 3
- Protein identifier
- P55017
Open Targets mechanisms
- Mechanism
- Thiazide-sensitive sodium-chloride cotransporter inhibitor
- Action type
- Inhibitor
- Target
- Solute carrier family 12 member 3
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- SLC12A3
- Protein identifier
- P55017
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Cardiovascular Diseases
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000319
- Subject identifier
- D002318
- Condition
- Heart Failure
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000373
- Subject identifier
- D006333
- Condition
- Hypertension
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000537
- Subject identifier
- D006973
- Condition
- Toxemia
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000668
- Subject identifier
- D014115
- Condition
- Multiple Sclerosis, Chronic Progressive
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003840
- Subject identifier
- D020528
- Condition
- Essential Hypertension
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0001134
- Subject identifier
- D000075222
- Condition
- Diabetes Mellitus, Type 2
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005148
- Subject identifier
- D003924
- Condition identifier
- EFO_0000319
- Condition identifier
- EFO_0000373
- Condition identifier
- EFO_0000537
- Condition identifier
- EFO_0000668
- Condition identifier
- EFO_0003840
- Highest recorded phase
- 2
- Condition identifier
- HP_0000822
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0001134
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004995
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005009
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005044
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005081
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005301
- Highest recorded phase
- 2
- Event
- acute kidney injury
- Reports
- 284
- Reporting signal score
- 397.878
- Event
- atrial fibrillation
- Reports
- 92
- Reporting signal score
- 79.1547
- Event
- blood pressure abnormal
- Reports
- 26
- Reporting signal score
- 41.0234
- Event
- blood sodium decreased
- Reports
- 42
- Reporting signal score
- 69.6202
- Event
- bundle branch block right
- Reports
- 20
- Reporting signal score
- 37.9614
- Event
- cardio-respiratory arrest
- Reports
- 26
- Reporting signal score
- 41.1373
- Event
- circulatory collapse
- Reports
- 28
- Reporting signal score
- 36.5505
- Event
- confusional state
- Reports
- 237
- Reporting signal score
- 310.933
- Event
- congenital bladder anomaly
- Reports
- 12
- Reporting signal score
- 56.8955
- Event
- conjoined twins
- Reports
- 20
- Reporting signal score
- 114.196
- Event
- dehydration
- Reports
- 97
- Reporting signal score
- 62.3957
- Event
- electrocardiogram qt prolonged
- Reports
- 55
- Reporting signal score
- 51.7646
- Event
- eosinophilia
- Reports
- 32
- Reporting signal score
- 34.9401
- Event
- fall
- Reports
- 175
- Reporting signal score
- 87.9436
- Event
- glomerular filtration rate decreased
- Reports
- 25
- Reporting signal score
- 37.488
- Event
- hyperkalaemia
- Reports
- 50
- Reporting signal score
- 46.7547
- Event
- hypertensive angiopathy
- Reports
- 7
- Reporting signal score
- 37.6243
- Event
- hypochloraemia
- Reports
- 30
- Reporting signal score
- 105.441
- Event
- hypokalaemia
- Reports
- 390
- Reporting signal score
- 1,043
- Event
- hypomagnesaemia
- Reports
- 100
- Reporting signal score
- 240.575
- Event
- hyponatraemia
- Reports
- 730
- Reporting signal score
- 2,207.94
- Event
- hyponatraemic seizure
- Reports
- 26
- Reporting signal score
- 124.846
- Event
- hypoosmolar state
- Reports
- 9
- Reporting signal score
- 42.3219
- Event
- hypotension
- Reports
- 159
- Reporting signal score
- 96.1146
- Event
- intestinal malrotation
- Reports
- 14
- Reporting signal score
- 61.2053
And 14 more, listed on the interactive page.
- NCT00122811
- NCT00128518
- NCT00295542
- NCT01620788
- NCT02710539
- NCT02710552
- NCT03246555
- NCT03814109
- NCT04455178
- NCT04518293
- NCT04518306
- NCT05103332
- NCT05110898
- NCT00145925
- NCT05013463
- NCT05878561
- Dose
- 10 mg/1.25 mg/0.625 mg to 40 mg/5 mg/2.5 mg
- Route
- Oral
- How often
- Once daily
- Do not cut, crush, or chew tablets
- May be taken with or without food
- Swallow tablets whole
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 2
- Polar surface area
- 92.5
- Calculated partition coefficient (ALogP)
- 2.08
- Calculated partition coefficient (XLogP)
- 2.9
- Prodrug
- No
- Chirality
- Racemic
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 24
- Molecular formula
- C16H16ClN3O3S
- Monoisotopic mass
- 365.0600902
- Natural product
- Yes
- 0228-2571
- 0228-2597
- 16571-875
- 16571-876
- 24338-001
- 24338-002
- 24338-003
- 51407-024
- 51407-025
- 62559-510
- 62559-511
- 72189-591
- 50090-7826
- 50090-7828
- 63629-1953
- 63629-1954
- 68788-7247
- 71335-1541
- 72162-1766
- 72162-1767
- Recorded assays
- 3,182
- Active assays
- 101
- Confirmatory
- Other
- Screening
- Summary
- Antihypertensive Agents
- Diuretics
- Sodium Chloride Symporter Inhibitors
Related records
Trials (36)
- A Comparison of Indapamide SR 1.5 mg With HCTZ 25 mg, in Combination With an ACE-inhibitor, in Patients With Mild to Moderate AHT and Type 2 DM
- A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy
- Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy
- Bioequivalence Study of 8 mg Perindopril Tert-Butylamine / 2.5 mg Indapamide / 10 mg Amlodipine Tablets Versus 10 mg Perindopril Arginine / 2.5 mg Indapamide / 10 mg Amlodipine Film-Coated Tablets in Healthy Volunteers
- Bioequivalence Study of 8 mg Perindopril Tert-butylamine / 2.5 mg Indapamide Tablets Versus 10 mg Perindopril Arginine / 2.5 mg Indapamide Film-coated Tablets in Healthy Volunteers
- Bioequivalence Study of Perindopril /Amlodipine/Indapamide 8 mg (10 mg)/2.5 mg/10 mg Tablets in Healthy Volunteers Under Fasting Conditions
- Comparison of Losartan Associated With Indapamide Versus Hyzaar® in the Hypertension Treatment
- Effect of Genetic Polymorphisms of UGT on the PKs of Indapamide in Egyptians
- Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension
- Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension
- Efficacy and Safety of Leningrado 5 Association in the Treatment of Hypertension
- Efficacy and Safety of Leningrado Association in the Treatment of Hypertension
- Efficacy and Safety Study of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension.
- Evaluating the Use of Oral Indapamide to Reduce Disabiltiy Progression in Progressive Multiple Sclerosis (MS)
- Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH)
- Fimasartan in the Senior Subjects
- Hydroxychloroquine and Indapamide in SPMS
- IDEAL Study: Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs
- Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone Prevention
- Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency
Approved for (4)
- Cardiovascular disorder
- Congestive heart failure
- Hypertensive disorder
- Preeclampsia
In development for (3)
- Chronic progressive multiple sclerosis Phase 2
- Essential hypertension Phase 3
- Type 2 diabetes mellitus Phase 3
Targets (1)
- SLC12A3 Thiazide-sensitive sodium-chloride cotransporter inhibitor